Dr. Michael Rome joined Foresite Capital in 2016 and leads the therapeutics investing practice. Michael is a board director at Kinnate Biopharma (Nasdaq: KNTE), Remix Therapeutics, XinThera, Theseus Pharmaceuticals (Nasdaq: THRX), and KinnJiu Pharma. Michael was a board director at Alumis where he led the acquisition of Fronthera Biopharma, and served on the board of Pharvaris (Nasdaq: PHVS), Turning Point Therapeutics (Nasdaq: TPTX, observer), and Nurix Therapeutics (Nasdaq: NRIX, observer). Michael served as Vice President for Foresite Development Corporation II which successfully merged with Pardes Biosciences (Nasdaq: PRDS). Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering therapeutics companies. He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and obtained his PhD in Biochemistry at Caltech as an NSF Fellow.
- Head of the therapeutics investment team at Foresite Capital, a multidisciplinary team comprising individuals with expertise in biopharma, finance, and academic science.
- Experience leading company formation, mergers and acquisitions, and private/public company structured financings.
- Board director and officer at multiple publicly traded biotechnology companies.